Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα ...
Jan 13, 2025 · INDIANAPOLIS and BOSTON, Mass., Jan. 13, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478. STX-478 is ...
Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα ...
INDIANAPOLIS and BOSTON, Mass., Jan. 13, 2025 — Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. (“Scorpion”), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kα inhibitor program STX-478.
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα ...
Jan 13, 2025 · Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to …
Jan 13, 2025 · Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.
Lilly inks $2.5B Scorpion buyout in twist to breast cancer tale
Jan 13, 2025 · Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics’...
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
Jan 14, 2025 · Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based ...
Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer …
Jan 13, 2025 · (RTTNews) - Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor program STX-478 for up to $2.5 billion in cash.
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion ...
Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. Subsequent payments to Scorpion shareholders are contingent upon the ...
Eli Lilly to acquire cancer program from Scorpion Therapeutics
Jan 13, 2025 · SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion ...
Jan 13, 2025 · The drugmaker said Monday it is acquiring Scorpion and its STX-478 program, with shareholders of the private company set to receive up to $2.5 billion in an upfront payment and subsequent...
- Some results have been removed